Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 15 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
EQUIPHARMA from Bertem, company number BE0475932379, closed financial year 2025 with a result of € 82,111 after tax. For that financial year EQUIPHARMA recorded a gross margin of € 85,141 and equity of € -75,256. Compared with financial year 2024, the result moved from € -262,349 to € 82,111. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on March 19, 2026.
€ -75,256
▲ € 82,111 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 82,111
▲ still € 262,349 loss in 2024
Profit after tax over the fiscal year.
€ 8,086
▲ € 7,529 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -81,456.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3,992
▼ 99% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 1,715
▲ 240% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 43,207 | € 57,672 | € 43,760 | € 85,141 | ▲ 95% |
| Profit after taxes | € 13,133 | € 24,952 | € -262,349 | € 82,111 | ▲ € 344,461 |
| Equity | € 92,030 | € 104,982 | € -157,367 | € -75,256 | ▲ € 82,111 |
| Total debts | € 78,213 | € 60,403 | € 323,977 | € 90,229 | ▼ 72% |
| Cash | - | - | € 557 | € 8,086 | ▲ € 7,529 |
| Land & buildings | € 82,203 | € 67,882 | € 53,562 | - | |
| Retained profit | € 85,830 | € 98,782 | € -163,567 | € -81,456 | ▲ € 82,111 |
| Dividend | € 0 | € 12,000 | € 0 | € 0 | |
| Bank debt | € 64,463 | € 42,635 | € 21,537 | € 0 | ▼ 100% |
| Balance sheet total | € 170,243 | € 165,385 | € 166,609 | € 14,973 | ▼ 91% |
Key figures of EQUIPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to EQUIPHARMA?
What happened at EQUIPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 82,111. Source: NBB ↗
- New establishment in Bertem. KBO
- Start of the company according to the CBE. KBO
In short
From € 13,133 profit in 2022 to € 82,111 profit in 2025.
Paid € 15,324 in corporate taxes since 2022.
Best year ever: 2025, with € 82,111 profit.
Paid out € 12,000 in dividends to the owners in total.
Management
Behind EQUIPHARMA is Diederik Vandeneede.
Directors
According to the 2025 annual accounts
Diederik Vandeneede
Director
Establishments
Establishment units
Physical locations of this company
W. Van Vlasselaerstraat 13
3061 Bertem
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0475.932.379
- VAT number
- BE 0475.932.379
- Registered office
- W. Van Vlasselaerstraat 13, 3061 Bertem
- Names & denominations
- EQUIPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 October 2001
- Peppol
- Active · Active since 12 Feb 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers